MSD

News

HIV, the AIDS virus (yellow), infecting a human cell

Gilead and MSD say weekly oral therapy controls HIV

Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.

News

Keytruda improves survival in early-stage kidney cancer

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell c

News

BMS' subcutaneous Opdivo clears first phase 3 trial

Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

News

Pharma CEOs may be subpoenaed as IRA dispute rumbles on

US Senator Bernie Sanders has said he plans to hold a vote on 31st January to subpoena the chief executives of Johnson & Johnson and Merck & Co for a hearing on dr

News

Keytruda breaks new ground in cervical cancer

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/

Gilead and MSD say weekly oral therapy controls HIV

Keytruda improves survival in early-stage kidney cancer

BMS' subcutaneous Opdivo clears first phase 3 trial

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

Pharma CEOs may be subpoenaed as IRA dispute rumbles on

Keytruda breaks new ground in cervical cancer

Consolidating data strategy for global success: Insights fro...

How to meet your physicians where they are online

MSD

Editor's Picks